TXMD250516P1000
- 0.05
- 0.000.00%
TherapeuticsMD Newsroom
TherapeuticsMD | 10-K/A: Annual report (Amendment)
TherapeuticsMD Inc. Stock Climbs 6.1%, Outperforms Market
TherapeuticsMD Inc. Stock Advances 11.4%, Outperforms Market
TherapeuticsMD Inc. Stock Slides 4.8%, Underperforms Market
TherapeuticsMD Inc. Stock Rallies 4.1%, Outperforms Market
AI replacing animal experiments? A message from the FDA has left "monkey breeders" feeling devastated, and experts state that "we are still far from the stage of implementation."
① The news that the USA FDA has publicly stated it will gradually replace animal testing requirements has led to an increase in the stock prices of AI pharmaceutical companies, impacting traditional drug evaluation CRO companies; ② Some believe this action represents a trend in Industry development. However, others believe that it is far from being implementable.
Mayne Pharma Faces Legal Challenge From TherapeuticsMD
TherapeuticsMD Full Year 2024 Earnings: US$0.20 Loss per Share (Vs US$0.74 Loss in FY 2023)
TherapeuticsMD Reports Reduced Losses and Revenue Growth
Therapeutics MD GAAP EPS of -$0.20
TherapeuticsMD | 10-K: FY2024 Annual Report
Express News | TherapeuticsMD FY24 EPS ($0.20) Up From ($0.74) YoY; Revenue $1.8M Up From $1.3M YoY
Press Release: TherapeuticsMD Announces Full Year 2024 Financial Results
Why GameStop Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
TherapeuticsMD Inc. Stock Rallies 10.4%, Outperforms Market
TherapeuticsMD Inc. Stock Sheds 3.3%, Underperforms Market
The tariff war between the US and Europe is escalating, and Trump's 'tariff big stick' is making the pharmaceutical industry tremble.
Pharmaceutical companies are urging the Trump administration and EU officials to exclude Medical products from the escalation of the trade war.
TherapeuticsMD Inc. Stock Advances 5.9%, Outperforms Market
New York Manufacturing Hits Low, Inflation Fears Rise
TherapeuticsMD Inc. Stock Sheds 10.0%, Underperforms Market